NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Metagenomi Therapeutics, Inc. MGX
3 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 25.2M
Revenue, FY2025 · full 3-year series below
Revenue $M
Net income $M
FY2025 · Revenue 25.2 · Net income -87.9
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−349 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -380.9% · Net -348.5%
ROE
FY2025 · ROE -44.7%
Each USD of equity lost 45 cents this year.
The 3-year record
3 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue $B | 0.0 | 0.1 | 0.0 |
| Operating income $B | −0.1 | −0.1 | −0.1 |
| EBITDA $B | −0.1 | −0.1 | −0.1 |
| Income tax $B | −0.0 | −0.0 | 0.0 |
| Net income $B | −0.1 | −0.1 | −0.1 |
| Free cash flow $B | −0.1 | −0.1 | −0.1 |
| EPS, diluted $ | −2.36 | −2.36 | −20.05 |
| Dividend / sh $ | · | · | · |
| Payout % | · | · | · |
| ROE % | −44.7 | −157.3 | · |
| Shares out B | 0.04 | 0.00 | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 12 reconciliationsAUDITED
Reconciled in 3 of 19 fiscal years. 64 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2023